

Contents

List of contributors	VII
Preface	XI
<i>Griffith Edwards</i>	
History of prevention of relapse	1
<i>Rainer Spanagel</i>	
How to measure relapse in animals	13
<i>Henry R. Kranzler and Howard Tennen</i>	
How to measure relapse in humans	23
<i>Dieter Ladewig and Ulrich von Bardeleben</i>	
Disulfiram (Antabuse®): the first medication to stop drinking	41
<i>Michael S. Cowen</i>	
Naltrexone: preclinical data	49
<i>Charles P. O'Brien, Helen M. Pettinati and David W. Oslin</i>	
Naltrexone: clinical data	59
<i>Philippe De Witte, Daniel Bachteler and Rainer Spanagel</i>	
Acamprosate: preclinical data	73
<i>Karl F. Mann</i>	
Acamprosate: clinical data	85
<i>Anh Dzong Lê and Douglas R. Funk</i>	
Serotonergic compounds: preclinical data	95
<i>Bankole A. Johnson</i>	
Serotonergic compounds: clinical data	107
<i>Petri Hyttiä</i>	
Opioidergic compounds: preclinical data	117

<i>John David Sinclair</i>	
Second generation opioidergic compounds: clinical data	125
<i>Friedbert Weiss</i>	
Dopaminergic compounds: preclinical data	135
<i>Gerhard A. Wiesbeck</i>	
Dopaminergic compounds: clinical data	155
<i>Mauro A.M. Carai, Roberta Agabio, Giovanni Addolorato, Gian L. Gessa and Giancarlo Colombo</i>	
Baclofen: preclinical data	163
<i>Giovanni Addolorato, Ludovico Abenavoli, Lorenzo Leggio, Giosuè DeLorenzi, Anna Ferrulli, Fabio Caputo, Roberta Agabio, Gian Luigi Gessa, Giancarlo Colombo and Giovanni Gasbarrini</i>	
Baclofen: clinical data	171
<i>Mauro A.M. Carai, Carla Lobina, Gian Luigi Gessa and Giancarlo Colombo</i>	
Cannabinoid receptor antagonists: a perspective	181
<i>Markus Heilig and Todd E. Thiele</i>	
Neuropeptide Y antagonists: a perspective	189
<i>Daniel Bachteler and Rainer Spanagel</i>	
Glutamatergic compounds: a perspective	205
<i>Rainer Spanagel and Karl F. Mann</i>	
Future perspectives on relapse prevention	217
Appendix – Chemical structures	227
Index	239